Show Summary Details
Page of

Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma 

Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma
Chapter:
Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma
Author(s):

Joshua Lovinger

DOI:
10.1093/med/9780199377527.003.0026
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 September 2019

This chapter provides a summary of a landmark study in neuro-oncology. Does MGMT promoter methylation confer benefit from temozolomide in patients with glioblastoma? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. This study demonstrated MGMT promoter methylation as a favorable prognostic factor in patients with glioblastoma. It also suggested that methylation status may help to predict which patients are most likely to benefit from alkylating chemotherapy. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.